Loading…
Loading…
I actually just had a quick question on your business in Asia
hoping you could just provide a little bit more color on sort of what drove that upside
how your away from home business trended in the quarter
how are you thinking about potential impacts on consumption from GLP-1 drugs. Have you seen any impact
how you'll ultimately balance growth and profitability for that business
can you give us a sense of how much this is being impacted by your pivot to smaller pack sizes
could you quantify the productivity savings you're hoping to generate this year? And how much above the typical $1 billion run rate it will be
how some of those investments are paying off? And then, if you're making any changes to your strategy, especially given the pressured consumer environment
Your EPS guidance assumes some leverage, but not nearly as much as you've reported in prior years
could you provide a little more color I guess, on what drove the weakness on volumes
your ranges are quite a bit wider than they've been historically. Now I certainly recognize there's a fair amount
based on your update, it still implies an acceleration in Q4 versus Q3. And then just, you know, thinking about that
curious how much flexibility you have to deliver on your EPS guidance range? And then in the context of that
Could you maybe frame for us or touch on the key growth drivers that really will allow you to deliver on your top and bottom-line guidance and possibly beat it
hoping you could talk a little bit more about the elasticities you're expecting, you know, with volumes I assume being pretty negatively impacted?
The stepped-up investments in The U.S, is this all Zen related or are you also accelerating spend behind IQOS or the full planned, you know, rollout of Illumina?
Did it actually bring in new consumers to the brand? And if so, I mean, can you give us a sense of what percentage of the free can promo resulted in new consumers to the brand?
I also want to understand the drivers behind your full year dollar EPS growth guidance raise despite the lower operating income growth guidance What are the drivers below the line?
How does that change your strategy, you know, as it relates for Zen, as it relates to, you know, your pricing, promotions
should we assume lower end of your full year shipment guidance range is more realistic?
how should we think about the drivers of continued margin expansion for the remaining of the year?
Could you maybe give us some more color on the out-of-stock issues you might still be experiencing in the U.S.?
hoping you could highlight the, you know, some of the key drivers behind this
you continue to target gross margin expansion in combustibles, And then you did say that you expect the gap to grow